Scarica l'app Stockscreener
20.91
3.33%
-0.72
Dopo l'orario di chiusura:
21.32
0.41
+1.96%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARQT Giù?
Forum
Previsione
Precedente Chiudi:
$21.63
Aprire:
$21.75
Volume 24 ore:
1.62M
Relative Volume:
0.92
Capitalizzazione di mercato:
$2.51B
Reddito:
$59.61M
Utile/perdita netta:
$-262.14M
Rapporto P/E:
-5.3342
EPS:
-3.92
Flusso di cassa netto:
$-247.49M
1 W Prestazione:
+0.97%
1M Prestazione:
+23.22%
6M Prestazione:
+61.34%
1 anno Prestazione:
+115.12%
Intervallo 1D:
$20.34
$21.84
Intervallo di 1 settimana:
$19.76
$21.84
Portata 52W:
$8.03
$21.84
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Nome
Arcutis Biotherapeutics Inc
Settore
Industria
Telefono
805-418-5006
Indirizzo
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Confronta ARQT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
20.91 | 2.45B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-25 | Iniziato | Goldman | Neutral |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-26 | Downgrade | Mizuho | Buy → Neutral |
| 2023-10-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-09-07 | Iniziato | Needham | Buy |
| 2022-03-17 | Iniziato | Goldman | Buy |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-05-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-10-08 | Iniziato | Truist | Buy |
| 2020-02-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Iniziato | Cowen | Outperform |
| 2020-02-25 | Iniziato | Goldman | Neutral |
| 2020-02-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie
Is Arcutis Biotherapeutics Inc. stock safe for conservative investorsTrade Entry Summary & Real-Time Buy Zone Alerts - newser.com
Is Arcutis Biotherapeutics Inc. stock dividend yield sustainableQuarterly Trade Report & Daily Stock Trend Reports - newser.com
Is Arcutis Biotherapeutics Inc. stock poised for growthWeekly Trade Report & Community Shared Stock Ideas - newser.com
Arcutis Biotherapeutics stock hits 52-week high at $21.56 By Investing.com - Investing.com Nigeria
How Arcutis Biotherapeutics Inc. stock reacts to Fed rate cutsWeekly Market Report & High Yield Stock Recommendations - newser.com
Arcutis Biotherapeutics stock hits 52-week high at $21.56 - Investing.com India
How Arcutis Biotherapeutics Inc. stock reacts to inflationary pressuresPortfolio Performance Summary & Fast Moving Stock Trade Plans - newser.com
Will a bounce in Arcutis Biotherapeutics Inc. offer an exitTrade Volume Summary & Risk Controlled Stock Pick Alerts - newser.com
What the charts say about Arcutis Biotherapeutics Inc. todayNew Guidance & Reliable Price Breakout Alerts - newser.com
How high can Arcutis Biotherapeutics Inc. stock goQuarterly Profit Summary & Low Drawdown Trading Techniques - newser.com
Can Arcutis Biotherapeutics Inc. hit a new high this monthQuarterly Portfolio Report & Precise Entry and Exit Recommendations - newser.com
Should you wait for a breakout in Arcutis Biotherapeutics Inc.July 2025 Big Picture & Free Long-Term Investment Growth Plans - newser.com
Has Arcutis Biotherapeutics Inc. found a price floorJuly 2025 EndofMonth & Low Risk Entry Point Tips - newser.com
How to interpret RSI for Arcutis Biotherapeutics Inc. stockJuly 2025 Movers & Technical Pattern Based Buy Signals - newser.com
Sentiment analysis tools applied to Arcutis Biotherapeutics Inc.Market Growth Report & Daily Market Momentum Tracking - newser.com
Arcutis Biotherapeutics Hits New 52-Week High of $21.55 - Markets Mojo
Arcutis Biotherapeutics reaches milestone recognized by Nasdaq - Traders Union
Wealth Enhancement Advisory Services LLC Purchases Shares of 15,666 Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Is Arcutis Biotherapeutics Inc. stock bottoming out2025 Price Momentum & Free Growth Oriented Trading Recommendations - newser.com
Arcutis Biotherapeutics (NASDAQ:ARQT) Hits New 1-Year HighStill a Buy? - MarketBeat
Arcutis Biotherapeutics stock hits 52-week high at 21.3 USD By Investing.com - Investing.com Australia
Arcutis Biotherapeutics stock hits 52-week high at 21.3 USD - Investing.com
Mizuho raises Arcutis Biotherapeutics stock price target to $26 on Zoryve sales - Investing.com
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 - BioSpace
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Raises Target Price to $26 - 富途牛牛
FDA approves ZORYVE cream for atopic dermatitis in young children By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells $90,260.16 in Stock - MarketBeat
Arcutis Biotherapeutics Hits New 52-Week High of $21.30 - Markets Mojo
FDA Approves Roflumilast Cream 0.05% for Atopic Dermatitis in Children 2 to 5 - Drug Topics
Arcutis Biotherapeutics stock rises after FDA approves eczema cream for young children - Investing.com
ARQT: FDA Approves ZORYVE Cream for Young Children's Atopic Derm - GuruFocus
FDA approves ZORYVE cream for atopic dermatitis in young children - Investing.com
Arcutis Biotherapeutics Inc Azioni (ARQT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Arcutis Biotherapeutics Inc Azioni (ARQT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Watanabe Todd | See Remarks |
Oct 01 '25 |
Sale |
19.33 |
24,261 |
469,074 |
867,179 |
| Watanabe Todd | See Remarks |
Oct 02 '25 |
Sale |
20.04 |
20,739 |
415,574 |
846,440 |
| Welgus Howard G. | Director |
Oct 01 '25 |
Option Exercise |
1.68 |
9,538 |
16,030 |
109,744 |
| Welgus Howard G. | Director |
Oct 01 '25 |
Sale |
18.92 |
10,000 |
189,227 |
99,744 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):